Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma

Blood

Volumn 100, Issue 1, 2002, Pages 224-229

  Spanswick, Victoria J ^a,b,c   Craddock, Charles ^a,b,c   Sekhar, Mallika ^a,b,c   Mahendra, Prem ^a,b,c   Shankaranarayana, Paneesha ^a,b,c   George Hughes, R ^a,b,c   Hochhauser, Daniel ^a,b,c   Hartley, John A ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c WEST MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMET ASSAY; CYTOTOXICITY; DNA ADDUCT; DNA CROSS LINKING; DNA REPAIR; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION;

EID: 0036660428     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.224     Document Type: Article

References (36)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
2. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
3. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822-824.
4. Dalton WS, Grogan TM, Meltzer PS, et al. Drug resistance in multiple myeloma and non-Hodgkins lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989;7:415-424.
5. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood. 1989;74:913-917.
6. Valkov NI, Sullivan DM. Drug resistance to DNA topoisomerase I and II inhibitors in human leukaemia, lymphoma and multiple myeloma. Semin Hematol. 1997;34:48-62.
7. Moalli PA, Pillay S, Weiner D, et al. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood. 1992;79:213-222.
8. Chauchan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227-234.
9. Hartley JA. Alkylating agents. In: Souhami RL, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford Textbook of Oncology. 2nd ed. Oxford, United Kingdom: Oxford University Press; 2002: 639-654.
10. Sunters A, Springer CJ, Bagshawe KD, et al. The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl) amino]benzoic acid. Biochem Pharmacol. 1992;44:59-64.
11. O'Connor PM, Kohn KW. Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustards. Cancer Commun. 1990;2:387-394.
12. Moscow JA, Swanson CA, Cowan KH. Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer. 1993;68:732-737.
13. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54:4313-4320.
14. Zwelling L, Michaels S, Schwartz H, et al. DNA crosslinking as an indicator of sensitivity and resistance of L1210 leukaemia cells to cis-diaminedichloroplatinum (11) and L-phenylalanine mustard. Cancer Res. 1981;41:640-649.
15. Hansson J, Lewensohn R, Ringborg U, et al. Formation and removal of DNA crosslinks induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res. 1987;47:2631-2637.
16. Hartley JA, Beradini MD, Souhami RL. An agarose gel method for the determination of DNA interstrand crosslinking applicable to the measurement of the rate of total and "second-arm" crosslink reactions. Ann Biochem. 1991;193:131-134.
17. Kohn KW, Ewig RAG, Erickson LC, et al. Measurement of strand breaks and crosslinks by alkaline elution. In: Friedberg EC, Hanawalt PC, eds. DNA Repair. New York, NY: Dekker; 1981:379-408.
18. Ostling O, Johanson KJ. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun. 1984;123:291-298.
19. Spanswick VJ, Hartley JM, Ward TH, Hartley JA. Measurement of drug-induced DNA interstrand crosslinking using the single cell gel electrophoresis (Comet) assay. In: Brown R, Boger-Brown U, eds. Methods in Molecular Medicine: Cytotoxic Drug Resistance Mechanisms. Vol 28.Totowa, NJ: Humana Press; 1999:143-154.
20. Hartley JM, Spanswick VJ, Gander M, et al. Measurement of DNA crosslinking in patients on Ifosfamide therapy using the single cell gel electrophoresis (Comet) assay. Clin Cancer Res. 1999;5:507-512.
21. Webley SD, Francis RJ, Pedley RB, et al. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer. 2001;84:1671-1676.
22. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353-1356.
23. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumour and normal cells measured using the "comet" assay. Radiat Res. 1990;122:86-94.
24. Bramson J, McQuillan A, Aubin R, et al. Nitrogen mustards drug resistant B-cell chronic lymphocytic leukaemia as an in vivo model for crosslinking agent resistance. Mutat Res. 1995;336:269-278.
25. Panasci L, Henderson D, Skalski V, et al. Transport, metabolism and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukaemia. Cancer Res. 1988;48:1972-1976.
26. Panasci L, Palement JP, Christodoulpoulos G, et al. Chlorambucil drug resistance in chronic lymphocytic leukaemia: the emerging role of DNA repair. Clin Cancer Res. 2001;7:454-461.
27. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001;2:483-490.
28. Torres-Garcia SJ, Cousineau L, Caplan S, et al. Correlation of resistance to nitrogen mustards in chronic lymphocytic leukaemia with enhanced removal of melphalan-induced DNA crosslinks. Biochem Pharmacol. 1989;38:3122-3123.
29. Geleziunas R, McQuillan A, Malapetsa A, et al. Increased DNA synthesis and repair enzyme expression in lymphocyte from patients with chronic lymphocytic leukaemia resistant to nitrogen mustards. J Natl Cancer Inst. 1991;83:557-564.
30. Bramson J, McQuillan A, Panasci LC. DNA repair enzyme expression in chronic lymphocytic leukaemia vis-a-vis nitrogen mustard drug resistance. Cancer Lett. 1995;90:139-148.
31. Barret J-M, Calsou P, Laurent G, et al. DNA repair activity in protein extracts of fresh human malignant lymphoid cells. Mol Pharmacol. 1996;49:766-771.
32. Muller C, Christodoulopoulos G, Salles B, et al. DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukaemia lymphocytes to nitrogen mustards. Blood. 1998;92:2213-2219.
33. Christodoulopoulos G, Malapesta A, Schipper H, et al. Chlorambucil induction of HsRad51 in B cell chronic lymphocytic leukaemia. Clin Cancer Res. 1999;5:2178-2184.
34. Tilby MJ, McCartney H, Gould KA, et al. A monofunctional derivative of melphalan: preparation. DNA alkylation products and determination of the specificity of monoclonal antibodies that recognize melphalan-DNA adducts. Chem Res Toxicol. 1998;11:1162-1168.
35. Nelms BE. Measuring apoptosis in individual cells with the Comet assay. Promega Notes. 1997;64:13-16.
36. Wang ZM, Chen ZP, Xu ZY, et al. In vitro evidence for homologous recombinational repair in resistance to melphalan. J Natl Cancer Inst. 2001;93:1473-1478.